Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Ранг среди акций #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Цена акции
$58.70
Последняя синхронизация: 2024-01-23
Рыночная капитализация
$2.98B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Mirati Therapeutics, Inc. (MRTX)

Категория

История дивидендной доходности для Mirati Therapeutics, Inc. (MRTX)
Дивидендная доходность (TTM) компании Mirati Therapeutics, Inc. (тикер: MRTX) на 2026 составляет: 0
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании Mirati Therapeutics, Inc. (MRTX) с 2026 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
Недостаточно данных для указанных дат.
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH